AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26393386 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 1 Hz rTMS
Number of subjects: 132
Study 26393386 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 10 Hz rTMS
Number of subjects: 132
Study 24193859 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based infusion therapy (ERT with agalsidase alfa every two weeks)
Number of subjects: 69
Study 21391018 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused intervention (n = 69)
Number of subjects: 183
Study 21391018 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-focused intervention (n = 58)
Number of subjects: 183
Study 21391018 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (control group, n = 56)
Number of subjects: 183
Study 19263348 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with vertigo (18 subjects)
Number of subjects: 32
Study 19263348 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (14 subjects)
Number of subjects: 32
Study 19263348 — intervention group
Group type: COMPARATOR
Intervention: Comparison between vertigo and control subjects
Number of subjects: 32
Study 19263348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar asymmetry evaluation
Number of subjects: 32
Study 17596725 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 0
Study 15557896 — intervention group
Group type: EXPERIMENTAL
Intervention: Powerlink bifurcated endovascular graft
Number of subjects: 258
Study 11439413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 110
Study 11439413 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 110
Study 9217961 — intervention group
Group type: EXPERIMENTAL
Intervention: Dubowitz score
Number of subjects: 839
Study 8481863 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning About AIDS
Number of subjects: 0
Study 3301457 — intervention group
Group type: EXPERIMENTAL
Intervention: twice daily sustained release theophylline suspension
Number of subjects: 14
Study 3301457 — intervention group
Group type: COMPARATOR
Intervention: standard twice daily slow release tablets
Number of subjects: 14
Study 2502937 — intervention group
Group type: EXPERIMENTAL
Intervention: Interposed abdominal compression CPR (IAC‐CPR)
Number of subjects: 33
Study 2502937 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR (S‐CPR)
Number of subjects: 33
Study 29783914 — intervention group
Group type: EXPERIMENTAL
Intervention: Fist Assist® device applied 15 cm proximal to arteriovenous fistula, enabling 60 mmHg of cyclic compression for 6 hours daily for 30 days
Number of subjects: 46
Study 29783914 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 46
Study 27464712 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid emulsion of coenzyme Q10 (250 mg daily for 1 week)
Number of subjects: 6
Study 27464712 — intervention group
Group type: COMPARATOR
Intervention: Solid formulation of coenzyme Q10 (250 mg daily for 1 week)
Number of subjects: 6
Study 27464712 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations (liquid emulsion and solid)
Number of subjects: 6
Study 25406242 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MeDiet) adherence
Number of subjects: 521
Study 25406242 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in carbohydrate intake (≤9.5 g/d)
Number of subjects: 521
Study 25406242 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA+PUFA/carbohydrates ratio increase
Number of subjects: 521
Study 23907233 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 0
Study 23907233 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogen
Number of subjects: 0
Study 23907233 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 0
Study 23907233 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21709611 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially stimulating group intervention
Number of subjects: 235
Study 21709611 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 235
Study 19394014 — intervention group
Group type: EXPERIMENTAL
Intervention: FFS (fine-threaded wires with a washer)
Number of subjects: 24
Study 19394014 — intervention group
Group type: COMPARATOR
Intervention: Tension band wiring
Number of subjects: 24
Study 16671835 — intervention group
Group type: EXPERIMENTAL
Intervention: Deaf participants (students with hearing loss)
Number of subjects: 62
Study 16671835 — intervention group
Group type: COMPARATOR
Intervention: Typical hearing participants (students without hearing loss)
Number of subjects: 62
Study 15562791 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) for more than 1 year
Number of subjects: 49
Study 15562791 — intervention group
Group type: COMPARATOR
Intervention: Non-ADT (control group)
Number of subjects: 49
Study 11520309 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK506)
Number of subjects: 12
Study 11520309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 12
Study 11520309 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 9261316 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunochromatography (IC)
Number of subjects: 130
Study 9261316 — intervention group
Group type: COMPARATOR
Intervention: Enzyme immunoassay (EIA)
Number of subjects: 130
Study 8301062 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidazole-salicylate (750 mg)
Number of subjects: 10
Study 8301062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3329078 — intervention group
Group type: EXPERIMENTAL
Intervention: Collatex vaginal contraceptive sponge
Number of subjects: 0
Study 3329078 — intervention group
Group type: COMPARATOR
Intervention: Neo Sampoon foaming vaginal contraceptive tablets
Number of subjects: 0
Study 30772584 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler Probe Examination (DPE)
Number of subjects: 100
Study 30772584 — intervention group
Group type: COMPARATOR
Intervention: Traditional Endoscopic Visual Assessment (TEA)
Number of subjects: 100
Study 28440105 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg/day
Number of subjects: 35
Study 28440105 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 8 mg/day
Number of subjects: 35
Study 28440105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 25467613 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity, low-amplitude manipulation of the cervical spine
Number of subjects: 10
Study 25467613 — intervention group
Group type: COMPARATOR
Intervention: Passive head-movement control
Number of subjects: 10
Study 24034602 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtotal hysterectomy (SH)
Number of subjects: 184
Study 24034602 — intervention group
Group type: COMPARATOR
Intervention: Total hysterectomy (TH)
Number of subjects: 184
Study 21167795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution
Number of subjects: 156
Study 21167795 — intervention group
Group type: COMPARATOR
Intervention: Single sodium phosphate enema
Number of subjects: 156
Study 18627372 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 9384
Study 18627372 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 9384
Study 18627372 — intervention group
Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 9384
Study 18627372 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 9384
Study 18627372 — intervention group
Group type: COMPARATOR
Intervention: Fumaric acid esters
Number of subjects: 9384
Study 16169681 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation fraction size 2 Gy (Arm A)
Number of subjects: 180
Study 16169681 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation fraction size 2.25 Gy (Arm B)
Number of subjects: 180
Study 12664317 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg, 2 times daily for 12 days
Number of subjects: 116
Study 12664317 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg for 12 days
Number of subjects: 116
Study 10360903 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted hatching using a piezo-micromanipulator
Number of subjects: 173
Study 10360903 — intervention group
Group type: COMPARATOR
Intervention: Nontreated embryos
Number of subjects: 173
Study 7567393 — intervention group
Group type: EXPERIMENTAL
Intervention: Color-specific method (Red Light Means Stop approach)
Number of subjects: 43
Study 7567393 — intervention group
Group type: COMPARATOR
Intervention: Conventional systems
Number of subjects: 43
Study 1718699 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem and aspirin administration
Number of subjects: 0
Study 1718699 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt cardiac catheterisation and myocardial revascularisation
Number of subjects: 0
Study 1718699 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise stress testing with 201Tl perfusion scintigraphy
Number of subjects: 0
Study 7103635 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxymesterone (30 mg/day) plus necessary transfusions
Number of subjects: 29
Study 7103635 — intervention group
Group type: COMPARATOR
Intervention: Transfusions only
Number of subjects: 29
Study 29736490 — intervention group
Group type: COMPARATOR
Intervention: 5% sodium fluoride varnish (positive control)
Number of subjects: 19
Study 29736490 — intervention group
Group type: COMPARATOR
Intervention: 3% potassium oxalate
Number of subjects: 19
Study 29736490 — intervention group
Group type: EXPERIMENTAL
Intervention: High power diode laser
Number of subjects: 19
Study 29736490 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step self-etching adhesive
Number of subjects: 19
Study 27046456 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP + IVB
Number of subjects: 33
Study 27046456 — intervention group
Group type: COMPARATOR
Intervention: PRP
Number of subjects: 33
Study 24495697 — intervention group
Group type: EXPERIMENTAL
Intervention: Priority Mail
Number of subjects: 976
Study 24495697 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive & Priority Mail
Number of subjects: 976
Study 24495697 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 976
Study 22450358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic heat pain at 42 °C
Number of subjects: 20
Study 22450358 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic heat pain at 46 °C
Number of subjects: 20
Study 22450358 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no stimulation)
Number of subjects: 20
Study 20665875 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 80
Study 20665875 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel‐eluting stent
Number of subjects: 80
Study 20665875 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic protection devices (EPDs)
Number of subjects: 80
Study 18534135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.2 mg once a day for up to 28 days
Number of subjects: 75
Study 18534135 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once a day for up to 28 days
Number of subjects: 75
Study 18534135 — intervention group
Group type: COMPARATOR
Intervention: Sodium diclofenac 50 mg twice a day for 10 days (Control)
Number of subjects: 75
Study 15777290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg kg(‐1) followed by 10 microg.kg(‐1).h(‐1)
Number of subjects: 31
Study 15777290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 20 microg kg(‐1) followed by 20 microg.kg(‐1).h(‐1)
Number of subjects: 31
Study 15777290 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 30 microg kg(‐1) followed by 30 microg.kg(‐1).h(‐1)
Number of subjects: 31
Study 15777290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alfentanil)
Number of subjects: 31
Study 12450889 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment (870 mg caffeine/d)
Number of subjects: 48
Study 12450889 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee treatment (0.9 L paper-filtered coffee providing approximately 870 mg caffeine/d)
Number of subjects: 48
Study 12450889 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (3 placebo capsules)
Number of subjects: 48
Study 12450889 — intervention group
Group type: COMPARATOR
Intervention: Coffee treatment (0.45 L coffee)
Number of subjects: 48
Study 9807846 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration of tenoxicam (10 mg in 10 ml normal saline)
Number of subjects: 60
Study 9807846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (20 mg)
Number of subjects: 60
Study 9807846 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam (10 mg)
Number of subjects: 60
Study 9807846 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative local infiltration or intravenous tenoxicam)
Number of subjects: 60
Study 7665863 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-week interferon-alpha course
Number of subjects: 88
Study 7665863 — intervention group
Group type: EXPERIMENTAL
Intervention: 52-week interferon-alpha course
Number of subjects: 88
Study 2611126 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinitar (purified coal tar cream)
Number of subjects: 30
Study 2611126 — intervention group
Group type: COMPARATOR
Intervention: 1% hydrocortisone cream
Number of subjects: 30
Study 415880 — intervention group
Group type: EXPERIMENTAL
Intervention: NH4Cl administration
Number of subjects: 0
Study 415880 — intervention group
Group type: COMPARATOR
Intervention: NH4HCO3 ingestion
Number of subjects: 0
Study 415880 — intervention group
Group type: EXPERIMENTAL
Intervention: HCl acidosis
Number of subjects: 0
Study 31931160 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Lavandula angustifolia Mill. Essential oil
Number of subjects: 52
Study 31931160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 30156312 — intervention group
Group type: EXPERIMENTAL
Intervention: Firocoxib (0.3 mg/kg, i.v. loading dose; 0.1 mg/kg, i.v., q24h)
Number of subjects: 56
Study 30156312 — intervention group
Group type: COMPARATOR
Intervention: Flunixin meglumine (1.1 mg/kg, i.v., q12h)
Number of subjects: 56
Study 28479288 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent Foley bulb and oxytocin
Number of subjects: 128
Study 28479288 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 128
Study 26542513 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel pretreatment (30 mg loading dose)
Number of subjects: 314
Study 26542513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 314
Study 26542513 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of CABG <2.98 days
Number of subjects: 314
Study 26542513 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of CABG ≥2.98 and <6.95 days
Number of subjects: 314
Study 26542513 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of CABG ≥6.95 days
Number of subjects: 314
Study 23510310 — intervention group
Group type: EXPERIMENTAL
Intervention: Any cataract
Number of subjects: 0
Study 23510310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear cataract
Number of subjects: 0
Study 23510310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical cataract
Number of subjects: 0
Study 23510310 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior subcapsular cataract (PSC)
Number of subjects: 0
Study 23510310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Number of subjects: 0
Study 23510310 — intervention group
Group type: COMPARATOR
Intervention: Age-related factors
Number of subjects: 0
Study 23510310 — intervention group
Group type: COMPARATOR
Intervention: Sex-related factors
Number of subjects: 0
Study 23510310 — intervention group
Group type: COMPARATOR
Intervention: Race-related factors
Number of subjects: 0
Study 22710541 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% KOH solution
Number of subjects: 50
Study 22710541 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin cream
Number of subjects: 50
Study 19266185 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 32
Study 19266185 — intervention group
Group type: EXPERIMENTAL
Intervention: Y + H (Yohimbine + Hydrocortisone)
Number of subjects: 32
Study 19266185 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone
Number of subjects: 32
Study 19266185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17264849 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg b.i.d.
Number of subjects: 38
Study 17264849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15230906 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen
Number of subjects: 57
Study 15230906 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen and 1000 mg acetaminophen
Number of subjects: 57
Study 15230906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 11350098 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval hypoxic training (three to four periods of 7 min progressive hypoxia in 1 h, each day for 14 days)
Number of subjects: 18
Study 11350098 — intervention group
Group type: COMPARATOR
Intervention: Control group (breathing into a spirometer)
Number of subjects: 18
Study 11350098 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval hypoxic training
Number of subjects: 18
Study 11350098 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 9164365 — intervention group
Group type: EXPERIMENTAL
Intervention: Acaricide (esdepallethin and piperonyl butoxide - 'Acardust') combined with environmental control
Number of subjects: 46
Study 9164365 — intervention group
Group type: COMPARATOR
Intervention: Continuous house dust mite avoidance measures
Number of subjects: 46
Study 9164365 — intervention group
Group type: COMPARATOR
Intervention: Placebo acaricide treatment combined with avoidance measures
Number of subjects: 46
Study 8778156 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (400 micrograms)
Number of subjects: 11
Study 8778156 — intervention group
Group type: EXPERIMENTAL
Intervention: Broxaterol (400 micrograms)
Number of subjects: 11
Study 8778156 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 11
Study 8778156 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + Broxaterol
Number of subjects: 11
Study 1975487 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 500 mg orally every 4 hours for 12 weeks, combined with six peripheral blood lymphocyte infusions and bone marrow transplantation
Number of subjects: 16
Study 1975487 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine, 100 mg every 4 hours for 12 months
Number of subjects: 16
Study 1975487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 81244 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxantrazole
Number of subjects: 13
Study 31611625 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches
Number of subjects: 3894
Study 31611625 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related factors
Number of subjects: 3894
Study 31611625 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status, international staging score, and molecular risk
Number of subjects: 3894
Study 31611625 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular events
Number of subjects: 3894
Study 31611625 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance status
Number of subjects: 3894
Study 30642296 — intervention group
Group type: EXPERIMENTAL
Intervention: PlasmaJet Surgical Device
Number of subjects: 330
Study 30642296 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical instruments combined with electrocoagulation (Control)
Number of subjects: 330
Study 28381202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 240
Study 28381202 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 24997634 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MSD)
Number of subjects: 49
Study 24997634 — intervention group
Group type: COMPARATOR
Intervention: Standard diet
Number of subjects: 49
Study 22268972 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-weekly group mantram intervention
Number of subjects: 32
Study 19892778 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 6500
Study 19892778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500
Study 18687149 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered telephone support with DVD education
Number of subjects: 210
Study 18687149 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered telephone counselling with DVD education
Number of subjects: 210
Study 18687149 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study 15854171 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipocol (2.4 g daily for 8 weeks)
Number of subjects: 88
Study 15854171 — intervention group
Group type: COMPARATOR
Intervention: Asacol (2.4 g daily for 8 weeks)
Number of subjects: 88
Study 14521276 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) treatment applied in the region with the highest theta/alpha ratio, triggering a sound when the ratio fell below a threshold value, 20 half-hour sessions at a rate of 2 per week.
Number of subjects: 10
Study 14521276 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent reinforcement (Control group).
Number of subjects: 10
Study 10383532 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 56
Study 10383532 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 56
Study 10383532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 7593419 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg every 8 h for 7 days)
Number of subjects: 7
Study 7593419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7593419 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone
Number of subjects: 7